Correlation Between Oncorus and Apexigen
Can any of the company-specific risk be diversified away by investing in both Oncorus and Apexigen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncorus and Apexigen into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Oncorus and Apexigen, you can compare the effects of market volatilities on Oncorus and Apexigen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncorus with a short position of Apexigen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncorus and Apexigen.
Diversification Opportunities for Oncorus and Apexigen
Pay attention - limited upside
The 3 months correlation between Oncorus and Apexigen is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Oncorus and Apexigen in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apexigen and Oncorus is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncorus are associated (or correlated) with Apexigen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apexigen has no effect on the direction of Oncorus i.e., Oncorus and Apexigen go up and down completely randomly.
Pair Corralation between Oncorus and Apexigen
If you would invest (100.00) in Apexigen on December 29, 2024 and sell it today you would earn a total of 100.00 from holding Apexigen or generate -100.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Oncorus vs. Apexigen
Performance |
Timeline |
Oncorus |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Apexigen |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Oncorus and Apexigen Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Oncorus and Apexigen
The main advantage of trading using opposite Oncorus and Apexigen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncorus position performs unexpectedly, Apexigen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apexigen will offset losses from the drop in Apexigen's long position.Oncorus vs. Apollomics Class A | Oncorus vs. Pyxis Oncology | Oncorus vs. Zura Bio Limited | Oncorus vs. Elevation Oncology |
Apexigen vs. Leap Therapeutics | Apexigen vs. Zura Bio Limited | Apexigen vs. X4 Pharmaceuticals | Apexigen vs. Phio Pharmaceuticals Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Complementary Tools
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |